Aktienanalyse zu Iovance Biotherapeutics Inc (IOVA)IOVAIovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Iovance Biotherapeutics Inc is a good buy right now due to its recent revenue guidance increase to $410-$420 million, reflecting a nearly 60% growth from last year, and a current price of $13.62, which is below several analyst price targets, including $20 from H.C. Wainwright. The stock has shown a strong year-to-date change of +440.48%, indicating robust momentum. However, the main risk is its negative earnings per share (EPS) of -0.11 reported last quarter, which highlights ongoing losses.

7 analysts cover IOVA: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.50.